MX2013010446A - Regimenes de dosificacion para el tratamiento de la enfermedad de fabry. - Google Patents

Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.

Info

Publication number
MX2013010446A
MX2013010446A MX2013010446A MX2013010446A MX2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A
Authority
MX
Mexico
Prior art keywords
treatment
fabry disease
dosing regimens
subject matter
disclosed subject
Prior art date
Application number
MX2013010446A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Stuart Greene
Kenneth Joseph Valenzano
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46831259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013010446(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2013010446A publication Critical patent/MX2013010446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01062—Glycosylceramidase (3.2.1.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
MX2013010446A 2011-03-11 2012-03-08 Regimenes de dosificacion para el tratamiento de la enfermedad de fabry. MX2013010446A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161451798P 2011-03-11 2011-03-11
US201161578201P 2011-12-20 2011-12-20
US201261596165P 2012-02-07 2012-02-07
PCT/US2012/028260 WO2012125402A2 (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease

Publications (1)

Publication Number Publication Date
MX2013010446A true MX2013010446A (es) 2014-03-27

Family

ID=46831259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010446A MX2013010446A (es) 2011-03-11 2012-03-08 Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.

Country Status (16)

Country Link
US (4) US20140219986A1 (OSRAM)
EP (2) EP2683382B1 (OSRAM)
JP (5) JP2014528901A (OSRAM)
KR (1) KR20140011367A (OSRAM)
CN (2) CN107088225A (OSRAM)
AU (6) AU2012229330B2 (OSRAM)
CA (1) CA2829947C (OSRAM)
CL (1) CL2013002601A1 (OSRAM)
EA (1) EA031874B1 (OSRAM)
ES (1) ES2807502T3 (OSRAM)
HK (1) HK1242998A1 (OSRAM)
MX (1) MX2013010446A (OSRAM)
SG (2) SG10201604757RA (OSRAM)
TW (3) TWI624258B (OSRAM)
WO (1) WO2012125402A2 (OSRAM)
ZA (1) ZA201306735B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137072A2 (en) 2006-05-16 2007-11-29 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
AU2009214648B2 (en) 2008-02-12 2014-11-13 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
KR102420934B1 (ko) 2013-03-11 2022-07-15 젠자임 코포레이션 과글리코실화된 결합 폴리펩티드
EP3108002A1 (en) * 2014-02-17 2016-12-28 GlaxoSmithKline Intellectual Property Development Limited Microbiological process
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN108351862B (zh) 2015-08-11 2023-08-22 科格诺亚公司 利用人工智能和用户输入来确定发育进展的方法和装置
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
WO2017165164A1 (en) * 2016-03-22 2017-09-28 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
TWI875676B (zh) * 2016-07-19 2025-03-11 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
JP7324709B2 (ja) * 2017-02-09 2023-08-10 コグノア，インク． デジタル個別化医療のためのプラットフォームとシステム
TWI795408B (zh) * 2017-05-30 2023-03-11 美商阿米庫斯醫療股份有限公司 治療有腎損傷的法布里患者的方法
CA3224529A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
CA3090496C (en) * 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
ES2993833T3 (en) * 2018-08-20 2025-01-10 Amicus Therapeutics Inc Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
EP3941340A4 (en) 2019-03-22 2022-11-30 Cognoa, Inc. Personalized digital therapy methods and devices
EP3947458A1 (en) 2019-04-03 2022-02-09 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
US20220313670A1 (en) * 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20240197706A1 (en) * 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2004069190A2 (en) * 2003-01-31 2004-08-19 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100457106C (zh) * 2005-06-15 2009-02-04 同济大学 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用
WO2007137072A2 (en) * 2006-05-16 2007-11-29 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2185187A1 (en) * 2007-08-29 2010-05-19 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a

Also Published As

Publication number Publication date
AU2012229330B2 (en) 2016-04-21
JP2017132780A (ja) 2017-08-03
AU2012229330A1 (en) 2013-10-03
AU2022203011A1 (en) 2022-05-26
AU2020201715A1 (en) 2020-04-09
SG193379A1 (en) 2013-10-30
AU2024205251A1 (en) 2024-08-22
JP2014528901A (ja) 2014-10-30
EP3698792A1 (en) 2020-08-26
CL2013002601A1 (es) 2014-03-28
NZ615726A (en) 2015-01-30
US20140219986A1 (en) 2014-08-07
TW201740945A (zh) 2017-12-01
CN103974619B (zh) 2017-02-15
CN103974619A (zh) 2014-08-06
US20240115708A1 (en) 2024-04-11
JP2021098697A (ja) 2021-07-01
ZA201306735B (en) 2014-07-30
EP2683382A4 (en) 2014-10-22
JP2023093448A (ja) 2023-07-04
CN107088225A (zh) 2017-08-25
EP2683382A2 (en) 2014-01-15
WO2012125402A2 (en) 2012-09-20
TW201634048A (zh) 2016-10-01
EA031874B1 (ru) 2019-03-29
EP2683382B1 (en) 2020-04-22
US20180153999A1 (en) 2018-06-07
AU2016204445A1 (en) 2016-07-21
WO2012125402A3 (en) 2014-05-01
JP2020033360A (ja) 2020-03-05
EA201301018A1 (ru) 2014-04-30
ES2807502T3 (es) 2021-02-23
HK1242998A1 (zh) 2018-07-06
TW201302197A (zh) 2013-01-16
AU2016204445B2 (en) 2018-03-22
US20200268890A1 (en) 2020-08-27
SG10201604757RA (en) 2016-08-30
CA2829947C (en) 2019-01-15
AU2018201637A1 (en) 2018-04-05
KR20140011367A (ko) 2014-01-28
TWI624258B (zh) 2018-05-21
CA2829947A1 (en) 2012-09-20
TWI624259B (zh) 2018-05-21

Similar Documents

Publication Publication Date Title
MX2013010446A (es) Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
GB201111485D0 (en) Drug composition and its use in therapy
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
PT2470199T (pt) Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida
MX2013009764A (es) Moduladores de receptores canabinoides.
NZ702469A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
IL260078B (en) Therapy used to treat Gaucher disease
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
EP2703006A4 (en) USE OF A CALCINEURIN 1 REGULATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ENHANCED NF-KB ACTIVITY
UA70710U (ru) Способ профилактики рецидивов аллергодерматозов у больных с вторичными иммунодефицитными состояниями
EP2692351A4 (en) ACTIVE FRACTION OF PAULLINIA CUPANA WITH IMPROVED EFFICACY AGAINST TEMPTATION, PROCESS FOR PREPARING AN ACTIVE FRACTION, USE THEREOF, PHARMACEUTICAL COMPOSITION, MEDICAMENTS AND TREATMENT FOR TREATMENT
UA65037U (ru) Способ лечения взрослых больных с соматоформными расстройствами
UA72002U (ru) Способ коррекции показателей системы фагоцитирующих макрофагов у больных туберкулезом легких
UA70775U (ru) Способ лечения менингококцемии у детей
UA65038U (ru) Способ лечения больных послеродовыми психозами
UA52520U (ru) Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста
UA59700U (ru) Способ лечения метаболического синдрома
UA69683U (ru) Способ лечения больных стеатогепатитом
UA33199U (ru) Способ коррекции показателей клеточного звена иммунитета у больных с соматоформными депрессивными расстройствами
UA33198U (ru) Способ коррекции иммунокомплексного спектра крови у больных соматоформными депрессивными расстройствами